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In approximately 15% of patients with spontaneous subarachnoid hemorrhage (SAH) a 
bleeding source is not determined in the initial neurovascular imaging. These patients are 
commonly categorized based on CT blood distribution into a perimesencephalic group and a 
non-perimesencephalic group (NPM-SAH), which is the subject of this study. Follow-up 
imaging is routinely performed in patients with spontaneous, angiogram-negative NPM-SAH 
to rule out a treatable etiology. However, the optimal follow-up imaging protocol for these 
patients remains unclear. Here, we examine the time to re-imaging after bleeding and the 
value of magnetic resonance angiography (MRA) in this setting. 
METHODS 
In this single-center, retrospective study, the medical records of patients treated at the 
University hospital of Zurich from 2007 to 2016 with NPM-SAH were analyzed and 
demographical, clinical and radiological data was collected. The re-imaging data was 
grouped according to imaging modality and into three categories according to time since 
bleeding: short-term (0-2 weeks), medium-term (2-8 weeks) and long-term (after 8 weeks). 
RESULTS 
30 patients with spontaneous, angiogram-negative NPM-SAH who received re-imaging were 
included in this study. Re-imaging revealed three true aneurysms, resulting in a diagnostic 
yield of 10.0%. All three aneurysms were detected during the period of medium-term re-
imaging, which was defined as 2-8 weeks after bleeding, and all three aneurysms were 
visible both on MRA and on digital subtraction angiography (DSA). The negative predictive 
value of DSA and MRA at day 14 post-bleeding was 85.7% and 91.3% respectively, and 
reached 100% for both imaging modalities at 8 weeks post-bleeding. Re-imaging led to two 
false-positive findings in which surgical exploration was negative, which resulted in a positive 
predictive value of 75% for MRA and 50% for CTA at 8 weeks. 
CONCLUSIONS 
We propose re-imaging for NPM-SAH patients during the periods of 10-14 days and 6-8 
weeks after bleeding. We suggest high-quality 3 Tesla MRA as a possible non-invasive 
alternative to DSA for re-imaging after NPM-SAH. In re-imaging after NPM-SAH, suspect or 
unclear findings on CTA or MRA should be corroborated on a DSA examination before 
performing surgical exploration to avoid false-positive findings. Long-term radiological follow-




2. LIST OF ABBREVIATIONS 
 
ACA  Anterior Cerebral Artery 
ACommA Anterior Communicating Artery 
CTA  Computer Tomography Angiography 
DCI  Delayed Cerebral Ischemia 
DSA   Digital Subtraction Angiography 
EVD  Extraventricular Drain 
GCS  Glasgow Coma Scale 
GOS  Glasgow Outcome Scale 
HCP  Hydrocephalus 
IA  Intracranial Aneurysm 
ICA  Internal Carotid Artery 
ICU  Intensive Care Unit 
LD  Lumbar Drainage 
MCA  Medial Cerebral Artery 
MRA  Magnetic Resonance Angiography 
MRI  Magnetic Resonance Imaging 
NPM-SAH Non-perimesencephalic Subarachnoid Hemorrhage 
NPV  Negative Predictive Value 
PCA  Posterior Cerebral Artery 
PCommA Posterior Communicating Artery 
PM-SAH Perimesencephalic Subarachnoid Hemorrhage 
PPV  Positive Predictive Value 
SAH  Subarachnoid Hemorrhage 
TOF-MRA Time-of-Flight Magnetic Resonance Angiography 
UIA  Unruptured Intracranial Aneurysm 
USZ  University Hospital of Zurich 
VBA  Vertebrobasilar Arteries 
VP-Shunt Ventriculoperitoneal Shunt 






3.1. Cerebral Aneurysms 
Aneurysms are pathological, localized bulging areas of blood vessels. Intracranial aneurysms 
(IAs) can be broadly classified based on shape into classical (saccular, or berry), fusiform 
and dissecting aneurysms, each with distinctive pathophysiology1,2. Saccular aneurysms 
comprise ninety percent of all cerebral aneurysms3. 
3.1.1. Localization and prevalence 
Although aneurysms can potentially form anywhere, IAs are most commonly found at the 
base of the brain, namely on the circle of Willis3. Specifically, they form near areas of high 
hemodynamic stress, such as vessel bifurcations1. In the majority of cases, they form on the 
anterior portion of the cerebral circulation, specifically the Anterior Cerebral Artery (ACA) and 
Anterior Communicating Artery (ACommA), followed by the Medial Cerebral Artery (MCA), 
the Internal Carotid Artery (ICA) and Posterior Communicating Artery (PCommA), with only 
about 15% forming on the posterior portion of the circulation, i.e. the Vertebrobasilar Artery 
(VBA)4. Multiple IAs are present in about a quarter of the patients5,6. It has been estimated 
that around 3% of the adult population carry unruptured saccular aneurysms7. 
3.1.2. Etiology and risk factors 
The majority of the aneurysms are thought to be – at least in part - the result of a congenital 
weakness in the vessel wall, specifically the tunica media6. Other, rarer causes include 
infections leading to mycotic aneurysms; trauma; and arteriosclerosis. 
Intracranial aneurysms are not a congenital disorder (i.e., the aneurysm itself is not present 
at birth8) but rather develop gradually. Several risk factors have been consistently shown to 
be associated with the formation of IAs, including hypertension, female sex, chronic alcohol 
use, smoking, and IAs in first-degree relatives9,10. The ethnic background of a patient has 
been associated with the incidence of aneurysmal subarachnoidal hemorrhage (aSAH)11 and 
patients with certain inheritable connective tissue disorders - particularly autosomal dominant 
polycystic kidney disease12 - also carry a higher risk of developing IAs.  
3.1.3. Risk of rupture 
Many prospective and retrospective studies have identified risk factors for the rupture of 
unruptured intracranial aneurysms (UIAs), albeit with varying levels of evidence. These 
include: Aneurysm size (being the most powerful risk factor2), younger patient age, aneurysm 
location (with posterior circulation aneurysms carrying a higher risk of rupture), previous 




irregular aneurysm morphology2,9,13–15. The largest meta-analysis of prospective cohort 
studies to date, including data of over 10’000 UIAs and 8000 patients and published in 2014, 
was used to develop the PHASES score estimating the absolute five-year risk of rupture 
based on six independent risk factors mentioned above14.  
3.1.4. Treatment 
Treatment of an aneurysm consists of excluding it from the arterial circulation. 
3.1.4.1. Endovascular Treatment 
The most commonly used endovascular treatment method is the Guglielmi detachable coil 
system, delivering platinum coils with a microcatheter through a guiding catheter, usually by 
entering through the femoral artery. By densely packing the aneurysm cavity with coils, it is 
occluded and thrombosis forms in its cavity, effectively removing it from the circulation. 
Further technical advances such as stent-assisted coiling and flow-diversion stenting (by 
which the stent is placed in the parent artery, altering hemodynamics thereby leading to 
gradual thrombosis of the aneurysm), have allowed more aneurysms – such as those with a 
wide neck - to receive endovascular management16–18. Endovascular treatment by selective 
coiling can be considered as first-line treatment for intracranial aneurysms of the posterior 
circulation and for many anterior circulation aneurysms (except for the MCA) – in young 
patients however, a surgical approach may be discussed in an interdisciplinary setting as 
endovascular coiling is known to be associated with a higher percentage of recanalization 
over time36,37. 
3.1.4.2. Surgical Treatment 
Surgical treatment, in particular clipping, involves a craniotomy followed by clipping of the 
base of the aneurysm with a titanium clip. This treatment method has evolved since its 
inception, particularly with the development of a wide variety of clips, minicraniotomy 
approaches such as minipterional and lateral supraorbital approaches, the use of 
intraoperative electrophysiological recordings of evoked potentials and the use of blood 
flowmeters19. Microsurgical clipping has been proven to be a safe and effective way to treat 
aneurysms with a low risk of recurrence20. 
Both treatment approaches have distinct benefits and drawbacks and the decision on how to 
best treat aneurysms remains a topic of debate, whereby individual characteristics, including 
aneurysm location and size as well as the clinical condition of each patient have to be taken 




3.2. Subarachnoid Hemorrhage 
Subarachnoid Hemorrhage (SAH) accounts for about 5% of all strokes and ca. 80% of 
spontaneous SAHs are of aneurysmal origin22 – although the leading cause for all SAHs 
remains trauma. Rarer causes of spontaneous SAH include the rupture of other vascular 
abnormalities such as arterio-venous malformations (AVMs), intracranial tumor hemorrhage, 
cerebral vein thrombosis or amyloid angiopathy23. If no bleeding source is detected in the 
initial diagnostic workup, one speaks of angiogram-negative SAH, as is discussed in detail in 
section 3.4. 
3.2.1. Symptoms and diagnosis 
SAH leads to a massive and sudden increase in intracranial pressure (ICP). Patients 
describe a sudden and very severe headache – described as the “first and worse” – which 
may be accompanied by nausea, vomiting, photophobia, nuchal rigidity and loss of 
consciousness24. Up to 40% of patients experience a sentinel headache, probably due to a 
“warning leak”, and subsequently have an increased risk of developing severe SAH with a 
high mortality risk in the following weeks6.  
Diagnosis of SAH is most often accomplished radiologically, with computer tomography (CT) 
being the first choice due to its availability, speed and high sensitivity in the acute setting25. 
Alternatively, MR Imaging (MRI), especially susceptibility-weighted imaging (SWI) or fluid 
attenuated inversion recovery (FLAIR) is useful and more sensitive than CT in detecting 
subarachnoid blood components already several days old26. In case of negative CT and 
clinical suspicion of SAH, a lumbar puncture is indicated to reveal hemoglobin breakdown 
products5. Following the diagnosis of SAH, neurovascular imaging such as CT-Angiography 
or digital subtraction angiography is mandatory to detect the source of the SAH, as is 
discussed in section 3.3. 
3.2.2. Prognosis 
Several studies in different populations have placed the overall 30-day mortality of 
aneurysmal SAH at 30-40% and the dependency rate of the survivors at 50%27–30. Non-
aneurysmal SAH patients, such as those suffering from a perimesencephalic SAH, have a 
better prognosis than aSAH patients, as discussed in section 3.4. Grading scores have been 
developed which provide a more exact prognosis based on the severity of the SAH, like the 
World Federation of Neurosurgeons Scale (WFNS), which is determined using the Glasgow 
Coma Scale (GCS) and the presence or absence of focal neurological deficits. The WFNS 
scale was conceived with the assumption that the most important predictor of mortality is 
conscious state31. Other established factors which influence prognosis include the patient’s 




and Hess scale is based on the patient’s clinical presentation and is used as a predictor of 
survival32. The Fisher scale, and more recently the modified Fisher scale, are common 
radiological grading systems based on the thickness and distribution of blood in the initial CT 
scan and correlate with vasospasm incidence33,34. 
3.2.3. Treatment and complications 
The main goals of SAH treatment are the prevention of rebleeding as well as the treatment 
and prevention of other complications. The exclusion of the bleeding source from the 
circulation should be done as soon as possible so as to prevent rebleeding and allow safe 
treatment of vasospasms9,35. As with unruptured aneurysms, microsurgical or endovascular 
treatment are available, and treatment decisions are made on a case-by-case basis. Large, 
randomized trials have been performed in recent years to compare these two methods in the 
case of ruptured aneurysms, such as the International Subarachnoid Aneurysm Trial (ISAT), 
a randomized trial including over 2000 patients, and the Barrow Ruptured Aneurysm Trial 
(BRAT), which have provided insight into the short- and long-term outcomes of patients 
treated with either method.9,36–40.  
The three main complications of SAH are rebleeding, delayed cerebral ischemia (DCI) and 
hydrocephalus. Due to these events, the first two weeks after the SAH have especially high 
mortality and morbidity rates38. Other possible complications include seizures, 
electrocardiographic abnormalities and electrolyte imbalances.  
The rebleeding risk is highest in the first days after SAH and rebleeding is associated with 
mortality rates of 50%24,41.  The risk is reduced by early aneurysm treatment. The high blood 
pressures often found after SAH due to elevated ICP and sympathetic activation also 
increase rebleeding risk and should be treated pharmacologically to pressures of around 
140-160mmHg6,9. There has been concern that lowering the blood pressure reduces brain 
perfusion due to the high ICP, and thus worsens clinical outcome. Studies addressing these 
concerns, however, did not find this to be the case42,43. 
The risk for DCI – which can occur with or without angiographically detectable vasospasm - 
is highest between days 7 and 10 after SAH and DCI significantly increases the risk of 
adverse outcome6. Detection of vasospasms can be done radiologically, i.e. using CT 
angiography or DSA. Transcranial ultrasound is a possibility for the monitoring of patients by  
measuring blood flow velocity in major vessels, with the ICA and MCA having the highest 
sensitivity44. The therapeutic approach to vasospasm is complex and subject to intense 
research. Nimodipine has been shown to improve neurologic outcome and should be given 
as prophylaxis to all patients with aSAH35,45. In case of symptomatic vasospasm, 




“triple H” therapy of  hypertension, hypervolemia, and hemodilution35,46. Endovascular 
approaches such as balloon dilatation or injection of nimodipine are also a possibility, though 
data is sparse9,35. 
Hydrocephalus – occlusive or communicating - can develop up to two weeks after the SAH, 
can become chronic, and is easily detectable in a CT scan. Treatment usually consists of 
placing an extraventricular drain (EVD) or lumbar drain (LD), or in the case of chronic 
hydrocephalus, a ventriculoperitoneal shunt (VP-Shunt)35. 
3.3. Neurovascular Imaging 
The field of neurovascular imaging aims at depicting the circulation of the brain and the 
spine. It is a rapidly evolving area with a multitude of techniques. In the context of SAH and 
aneurysms however, three techniques are of distinct importance: CT-Angiography (CTA), 
MR-Angiography (MRA) and Digital Subtraction Angiography (DSA). 
3.3.1. CT-Angiography 
CTA uses intravenous iodinated contrast agent to image vessels and can be performed 
immediately following the CT scan in which SAH is diagnosed. It enjoys excellent detection 
rates of nearly 100% for aneurysms larger than 3mm25,47,48 and technological advancements 
are improving its detection capacity for smaller aneurysms and aneurysms close to the skull 
base49. As in the other imaging modalities, 3D reconstruction of the images is critically helpful 
in diagnosing vascular lesions and in characterizing their vascular anatomy. Overall, recent 
large studies have shown that the detection gap for aneurysms to DSA is closing50,51, making 
CTA a vital tool for the rapid diagnostic workup needed following SAH. The main drawbacks 
of this technique are its use of a potentially nephrotoxic and anaphylactogenic contrast agent 
as well as its exposure to radiation. 
3.3.2. MR-Angiography 
Several methods exist in order to depict vessels using magnetic resonance imaging. These 
can be broadly classified into flow-based methods, which do not use contrast agents, and 
contrast-agent based methods, which use a gadolinium-containing contrast agent. The most 
commonly used flow-based method is Time-of-flight MRA (TOF-MRA).  
A large meta-analysis published in 2014 provided important data on the diagnostic utility of 
MRA regarding aneurysms52. In particular, the diagnostic performance of TOF-MRA and 
contrast-enhanced methods were not significantly different, and 3 Tesla MR imaging 
performed better than 1.5 Tesla imaging. Moreover, the value of 3D reconstruction of the 
images was clearly demonstrated in this study, as it significantly improved diagnostic 




but with a lower specificity of 89%, indicating a comparatively high number of false-positive 
findings. Due to its longer runtime, lesser availability and higher susceptibility to motion 
artifacts, MRA is rarely used in the acute setting. 
3.3.3. Digital Subtraction Angiography 
DSA is an invasive, catheter-based fluoroscopic technique by which an X-Ray contrast agent 
is directly injected into the artery in question, and the pre-contrast image is subtracted from 
the subsequent contrast films. DSA, especially 3D rotational angiography remains the gold 
standard for the detection of aneurysms thanks to its excellent, sub-millimeter spatial and 
high temporal resolution5,47. This resolution allows precise characterization of the relationship 
of the aneurysm to its parent artery and to any neighboring small arterial branches, which is 
crucial for the diagnostic workup of the patient and for the treatment decisions. As such, it 
remains the best diagnostic tool for the depiction of the vascular anatomy. DSA is associated 
with complications (such as stroke or vascular injury), however the rate of complications is 
low (ca. 0.3%) and most of these complications are not permanent53. Finally, DSA remains a 
time-consuming, expensive and somewhat invasive technique5. Similar to CTA, its additional 
limitations are the use of contrast agent and its exposure to radiation.  
3.4. Angiogram-negative subarachnoid hemorrhage 
Cases in which no bleeding source is visible in the initial imaging occur in up to 20% of the 
spontaneous SAH patients54. Over the course of the last 2 decades, it has become common 
in the literature to divide these patients into two subgroups. These two groups require 
different diagnostic and therapeutic approaches.  
3.4.1. Perimesencephalic subarachnoid hemorrhage 
Perimesencephalic subarachnoid hemorrhage (PM-SAH) is a distinct type of hemorrhage 
which is defined by the following criteria55: Subarachnoid blood located in the midbrain 
(pretruncal)  cisterns, with its center directly anterior to the midbrain and with no extension of 
the hemorrhage to the lateral Sylvian fissures or to the anterior part of the interhemispheric 
fissure. Furthermore, no frank intraventricular hemorrhage (some sedimentation in the 
posterior horns is allowed) or extension of the hemorrhage into the brain parenchyma is 
permitted. The clinical symptoms upon bleeding are relatively mild, with patients fully 
conscious. As such, the bleeding source is believed to be of venous, as opposed to arterial, 
origin56. 
If the blood localization has been classified as perimesencephalic and no bleeding source 
has been determined in a high-quality CTA or DSA, no further diagnostic workup is 
necessary, as later re-imaging has consistently been shown to reveal bleeding sources only 




diagnostic yield57. These patients enjoy excellent recovery and low complication rates, and 
as such can be discharged within a few days after bleeding and generally do not require 
long-term clinical follow-up58–60. 
3.4.2. Non-perimesencephalic subarachnoid hemorrhage 
The patients with diffuse CT blood distribution which is not confined to the pretruncal cisterns 
form an etiologically heterogenous group termed non-perimesencephalic subarachnoid 
hemorrhage (NPM-SAH). Several publications have shown that these patients, contrary to 
PM-SAH patients, develop typical complications seen in aneurysmal SAH patients – in 
particular hydrocephalus and vasospasm, but also severe neurological deficits such as 
central facial palsy or hemiparesis - , albeit less frequently61–65. For this reason, patients with 
NPM-SAH are commonly treated akin to aneurysmal SAH patients. 
The diagnostic yield of second-look imaging, especially using DSA, has been reported to be 
up to 20% in the recent literature66–69, with a thrombosed or dissecting aneurysm a possible 
cause70. Rarer causes such as arteriovenous malformations (AVM), spinal vascular lesions 
or dural arteriovenous fistula have been described as well22. Based on these findings, the 
guidelines European Stroke Organization recommend re-imaging using CTA or DSA 3 weeks 
or later after bleeding, if there are no indications to perform it earlier57. 
It is vitally important to rule out a treatable etiology in these patients to prevent rebleeding, 
which is often lethal. However, the optimal protocol for follow-up imaging of patients with 
spontaneous NPM-SAH and initially negative vascular imaging is unclear. To this day, 
patients receive imaging to the discretion of the treating surgeon, with many institutions and 
hospitals having empirically developed individualized follow-up imaging and treatment 
protocols. In particular, the value of noninvasive alternatives to DSA like MRA remains 
largely unexplored in the literature, as does the optimal time to re-imaging after bleeding. 
These issues are at the heart of this study. 
3.5. Research questions 
The following research questions are addressed in this study: 
1. When is neuroimaging needed after spontaneous, angiogram-negative NPM-SAH?  
 
2. Is high-quality, 3 Tesla MRA a noninvasive alternative to DSA for follow-up imaging of 




4. MATERIALS AND METHODS 
 
4.1. Setting and patients 
In this retrospective, single-center study, the medical records of patients with spontaneous, 
angiogram-negative NPM-SAH were reviewed. The University Hospital of Zurich (USZ) is a 
tertiary referral hospital to which patients with SAH are transferred from a large geographical 
area due to its neurosurgical treatment capabilities.  
A list of patients treated in the USZ with NPM-SAH was compiled dating back to 2007. These 
patients were included based on the following criteria: Patients presenting themselves with 
spontaneous SAH diagnosed radiologically or through lumbar puncture, with no bleeding 
source in the first CTA and DSA and with the subarachnoid blood distribution not confined to 
the midbrain cisterns - i.e. reaching the lateral Sylvian fissures or the anterior part of the 
interhemispheric fissure -, or with intraventricular or intraparenchymal blood. Patients with 
traumatic brain or extensive head injuries were excluded from the analysis.  
4.2. Data collection and statistical analysis 
Data from the medical records of the included patients was collected. Demographic data 
such as age and gender, radiological data including the type and time of the diagnostic 
imaging and of the follow-up imaging, and clinical information such as neurological status on 
presentation, complications while hospitalized and relevant comorbidities was gathered. Day 
0 was defined as the day the bleeding occurred.  
The initial SAH severity was determined using the Hunt and Hess score, the WFNS score, 








Table 1: The Hunt and Hess score 
The Hunt and Hess score 
1 mild headache 
2 
Cranial nerve palsy/severe 
headache/nuchal rigidity 
3 





















             Table 3: The Fisher scale 
 
Follow-up imaging was characterized based on the time it was performed post-bleeding, the 
imaging modality that was used and the presence of relevant findings. 
Data was collected in Microsoft Excel in encrypted fashion in which the patients were 
assigned a neutral number, and a separate spreadsheet was compiled in which the neutral 
numbers were linked to the patient numbers of the USZ registry. All statistical analysis was 
done using SPSS Version 24. 
To answer research question 1, re-imaging results were categorized into different time 
periods post-bleeding: short-term (0-2 weeks), medium-term (2-8 weeks), and long-term (>8 
weeks). The negative predictive value of re-imaging during these time periods was calculated 
and used to gauge the need for further re-imaging beyond these time periods. 
To address research question 2, the diagnostic yield of MRA and DSA was assessed, along 
with their respective negative predictive values. Furthermore, the positive predictive value of 
MRA was determined, as a marker for its reliability in detecting true aneurysms. 
 
The WFNS score 
Grade GCS Motor deficit 
1 15 Absent 
2 13-14 Absent 
3 13-14 Present 
4 7-12 Present or absent 
5 3-6 Present or absent 
 The Fisher scale 
1 No SAH visible radiologically 
2 SAH thickness <1mm 
3 SAH thickness >1mm, no 
intraventricular hemorrhage 






The cantonal ethics committee of the canton of Zurich has approved this study under the 
Project ID 2018-02027 („Re-imaging after spontaneous, non-perimesencephalic 
subarachnoid hemorrhage with initially negative angiogram: which type of neuroimaging is 
needed, and when?”). The application for this project used the template „Weiterverwendung 
biologischen Materials und/oder gesundheitsbezogener Personendaten für die Forschung 
bei fehlender Einwilligung und Information nach Artikel 34 HFG“, with Dr Esposito as the 
project leader. 
Only patients who had no documented refusal to participate in clinical studies were included 
in this project. Furthermore, from 2016 onwards, only patients who filled out the form 
“Generalkonsent” of the University Hospital of Zurich were included, thereby consenting to 
the anonymous usage of their biological and clinical data for research purposes. 
Anonymity was ensured by assigning each patient a neutral number during the data 
collection, and compiling a password-protected table in which the neutral numbers were 
assigned to the patient number of the USZ registry KISIM. Only the student and the 
supervisor Dr. Esposito had access to this table. Collected, encrypted patient data was 








32 patients were initially included in this study. These patients were admitted to the USZ with 
spontaneous NPM-SAH for which no bleeding source on initial CT-Angiography (CTA) or 
Digital Subtraction Angiography (DSA) was detected.   
5.1. Patient characteristics 
Of the 32 patients included in the study, 13 were female and 19 were male. The mean age 
was 62, with a range of 31-97.  
PATIENT CHARACTERISTIC NUMBER OF PATIENTS 
AGE 62.0 (range 31-97) 
FEMALE:MALE 13:19 (40.6%:59.4%) 
HUNT&HESS I 12 (37.5%) 
II 13 (40.6%) 
III 1 (3.1%) 
IV 4 (12.5%) 
V 2 (6.3%) 
WFNS             I 18 (56.3) 
II 8 (25%) 
III 0 (0%) 
IV 3 (9.4% 
V 3 (9.4%) 
FISHER           I 1 (3.1%) 
II 2 (6.3%) 
III 14 (43.8%) 
IV 15 (46.9%) 
GCS               3-6 5 (15.6%) 
7-9 1 (3.1%) 
10-12 3 (9.4%) 
13-15 23 (71.0%) 
                     Table 4: Patient Characteristics 
 
5.2. Initial diagnostic imaging 
All SAHs were diagnosed by CT or MR scans except in one patient for whom the SAH was 
detected by lumbar puncture, whereby the subarachnoid blood was then seen in an 
MRI/MRA exam one day after diagnosis. 
All patients received a CTA scan as a first vascular imaging modality except for two patients: 
In one case, MRA was performed because of an allergy to CT contrast agent and renal 




performed in a private practice as prescribed by the family physician after five days of 
cephalic pain.  
In 4 cases, the initial CTA scan was performed in a peripheral hospital before the patient was 
transferred to the university hospital. In one of these cases, CTA was repeated in-house 3 
hours after the first CTA once the patient had been transferred. 
In all patients, the initial negative CTA or MRA after SAH diagnosis was followed within 24h 
by a DSA except in 6 cases: In one patient, DSA was not performed because of diabetic 
microangiopathy. Another patient developed severe renal insufficiency after the initial CTA. 
In three cases, the patients either died or their status was too critical to undergo DSA. In one 
patient, no explanation was found in the records for the omission of DSA at that point in time, 
although MRA was performed two days after the initial CTA and DSA subsequently one day 
later. 
5.3. Clinical course 
Of the 32 patients with angiogram-negative SAH, 30 patients received re-imaging, and two 
patients died from the bleeding before re-imaging could be performed.  
All patients were treated in the ICU according to standard clinical practice for subarachnoid 
hemorrhage treatment. Of the patients receiving re-imaging, 2 died (6.7%, Table 5): One 
patient died of severe pneumonia twelve weeks after bleeding, while one patient died of 
cardiac arrest 15 days after bleeding.  
15 patients (50%) developed hydrocephalus. Of these, 13 patients received an EVD, 7 
patients a LD and 6 were finally treated with a VP Shunt. 4 patients (13.3%) experienced 
symptomatic vasospasm.  
All but 3 patients were followed-up at least once clinically after 8 weeks: one patient was 
transferred to his home country after 15 days. One patient did not wish any more follow-ups 
after 40 days. The third patient died of cardiac arrest at day 15 as outlined above. However, 
the long-term clinical outcome of the patient series using either the modified Rankin Scale 
(mRS) or the Glasgow Outcome Scale (GOS) could not be adequately gathered due to the 
inconsistency of its documentation with these scales during clinical follow-up. None of the 
















Table 5: Clinical course 
 
5.4. Re-imaging after bleeding 
30 patients received re-imaging, consisting of CTA (12 patients), DSA (16 patients), 3 Tesla 
brain TOF-MRA (27 patients) and 3 Tesla neck TOF-MRA (3 patients). The three modalities 
were performed at different time points for each patient, and were often repeated for each 
patient.  
Re-imaging revealed 3 true aneurysms (10.0% yield) and 2 false positive findings (6.7%). 
For presentation, re-imaging was categorized into five time periods since bleeding: 1-7 days, 
8-14 days, 2-8 weeks, 2 weeks-1 year, >1 year (Table 6). 
 
FOLLOW-UP IMAGING 
MODALITY DAYS SINCE HEMORRHAGE 
 1-7 
days 




DSA: # OF EXAMINATIONS 4 10 5 2  
# OF PATIENTS 4 10 5 2  
TRUE POSITIVE - - 2 detected 
1 confirmed 
- - 
FALSE-POSITIVE - - - - - 
CTA: # OF EXAMINATIONS 6 7 3 5  
# OF PATIENTS 5 6 3 2  
TRUE POSITIVE - - 1 confirmed - - 
FALSE-POSITIVE 1 - - - - 
MRA: # OF EXAMINATIONS 12 14 7 22 8 
# OF PATIENTS 12 14 7 19 7 
TRUE POSITIVE - - 1 detected 
2 confirmed 
- - 
FALSE-POSITIVE - 1 - - - 
 Table 6: follow-up imaging by days after bleeding 
 
 
COMPLICATION NUMBER OF PATIENTS 
DEATH 2 (6.7%) 
HYDROCEPHALUS 15 (50.0%) 
EVD 13 (43.3%) 
LD 7 (23.3%) 
VP SHUNT 6 (20.0%) 
SYMPTOMATIC VASOSPASM 4 (13.3%) 
RE-BLEEDING 0 (0%) 
MEAN DAYS IN ICU (DEATHS EXCLUDED) 12.5 (range 1-23) 




For analysis, re-imaging was categorized into: 
- short-term re-imaging: within the first 14 days after bleeding (during the acute phase, 
while the patient is still hospitalized)  
- medium-term re-imaging: from two to eight weeks after bleeding 
- long-term re-imaging: later than eight weeks after bleeding 
 
5.4.1. True aneurysms 
Regarding the three true aneurysms detected during follow-up imaging, an aneurysm of the 
pericallosal artery was shown in a DSA and in MRA 44 days after bleeding. In the second 
case, a basilar aneurysm was seen in a DSA 39 days and in MRA 44 days after bleeding. In 
the third case, a carotid paraclinoidal aneurysm was seen on MRA 20 days after bleeding, 
thereafter further confirmed by CTA and DSA (21st-23rd day). The pericallosal and the basilar 
aneurysms were determined to be the bleeding sources. The paraclinoidal aneurysm was 
shown intraoperatively not to be in the subarachnoid space and therefore not to be the 
source of the bleeding.  
In these 3 cases, the first re-imaging was performed on day 1 (MRA, for the pericallosal 
aneurysm), on day 11 (CTA, for the basilar aneurysm), and on day 4 (CTA, for the 
paraclinoidal aneurysm). Before detection of the aneurysm, DSA re-imaging was performed 
only for the pericallosal aneurysm (day 5) and for the paraclinoidal aneurysm (day 8) (Table 
7).  
All these 3 true aneurysms could be identified on MRA as well as DSA. They were all 
detected during medium term re-imaging (2-8 weeks after bleeding).  
FOLLOW-UP IMAGING 
MODALITY DAYS SINCE BLEEDING 
 1-7 days 8-14 days 2-8 weeks 8 weeks 
– 1 year 
>1 year 
PATIENT 1 (PERICALLOSA)      
DSA:  day 5  day 44   
CTA:       
MRA: day 1  day 44   
PATIENT 2 (BASILAR)      
DSA:    day 39   
CTA:   day 11 day 17   
MRA:   day 44   
PATIENT 3 (PARACLINOIDAL)      
DSA:   day 8 day 21   
CTA:  day 4  day 23   
MRA: day 7  day 20   




5.4.2. False-positive findings 
Concerning the two false positive imaging results (6.7%), one was seen in a CTA performed 
2 days after bleeding, which was a dilation of the A1 segment of the ACA that was judged to 
be a potential aneurysm by the treating surgeon. In the second case, a saccular aneurysm at 
the bifurcation of the right MCA was suspected on MRA 11 days after bleeding. These two 
patients underwent surgical exploration, however intra-operatively no aneurysm was found. 
In both cases no DSA was performed before surgery, and in both cases the false-positive 
finding was found in the first re-imaging instance, during short-term follow-up (within two 
weeks after bleeding).  
The positive predictive value (PPV) of MRA re-imaging in the first eight weeks was therefore 
75% (3 true positives / (3 true positives + 1 false positive), while that of CTA was 50 % (1 
true positive / (1 true positive + 1 false positive).  
5.4.3. Negative predictive values 
23 patients received MRA re-imaging at short term follow-up (within 14 days after bleeding). 
7 patients received MRA re-imaging at medium term follow-up (from day 15th to 8 weeks after 
bleeding), for a total of 24 patients receiving MRA re-imaging from day 1 to week 8. 19 
patients received long-term MRA follow-up (>8 weeks post-bleeding) (table 6). 
The negative predictive value (NPV) of MRA re-imaging in the first two weeks after bleeding 
was 91.3% in our series (21/23 = 21 true negatives / (21 true negatives + 2 false negatives)). 
The NPV of MRA at medium-term re-imaging was 100% (4 true negatives / 4 true negatives) 
as no relevant lesions were found in long-term MRA follow-up (19 patients). 
14 patients received DSA re-imaging at short term follow-up (within 14 days after bleeding). 5 
patients received DSA re-imaging at medium term follow-up (from day 15th to 8 weeks after 
bleeding) and 2 patients received DSA after eight weeks (table 6).  
The NPV of DSA in the first 2 weeks was 85.7% (12 true negative / 12 true negative + 2 false 






6.1. Key findings 
30 patients with spontaneous, angiogram-negative NPM-SAH who received re-imaging were 
included in this retrospective study. Re-imaging revealed three true aneurysms, resulting in a 
diagnostic yield of 10.0%. All three aneurysms were detected during the period of medium-
term re-imaging, which was defined as 2-8 weeks after bleeding, and all three aneurysms 
were visible both on MRA and on DSA. Two of these aneurysms were determined to be the 
bleeding source of the SAH.  
The negative predictive value of DSA and MRA at day 14 post-bleeding was 85.7% and 
91.3%, respectively, and reached 100% for both imaging modalities at 8 weeks post-
bleeding. No relevant findings were seen during long-term re-imaging after 8 weeks in any of 
the 20 patients receiving follow-up imaging in that time period. 
Re-imaging lead to two false-positive findings (one on CTA and one on MRA) in which both 
patients underwent surgical exploration which did not reveal an aneurysm. This resulted in a 
positive predictive value of 75% for MRA and 50% for CTA at 8 weeks. Neither patient had 
undergone a DSA examination prior to the surgical exploration. 
6.2. Comparison with the recent literature 
6.2.1. Value of MRA re-imaging 
The literature has consistently shown the diagnostic value of re-imaging in NPM-SAH 
patients, especially of re-imaging using DSA. Two meta-analysis published in 2014 and 
2017, investigating the yield of repeat DSA in this patient group have placed the diagnostic 
yield of repeat DSA at 10.0% (368 total patients)66 and 12.6% (556 total patients)71 
respectively – although there was considerable variation in the diagnostic yield as well as 
sample sizes of the included studies in both cases. We can confirm the value of DSA re-
imaging, with all true aneurysms visible on DSA re-imaging, resulting in a diagnostic yield of 
this imaging modality in our series of 10.0%. Furthermore, both aneurysms determined to 
have been the bleeding source were first detected on DSA. However, as all true aneurysms 
in our series were visible on MRA imaging as well, our study supports the notion that high-
quality 3T MRA might be considered as a non-invasive alternative to DSA for re-imaging of 
NPM-SAH patients.  
This finding is in contrast to some of the recent publications which have often not been able 
to show the value of MRA re-imaging, although the quality of the data is wanting and 
inconsistent: details on MR sequences and on the timing of re-imaging after bleeding is 




reported no new lesions detected by MR re-imaging in 63 patients (both PM-SAH and NPM-
SAH patients): the timing of the MR examination however is not reported; furthermore, the 
number of patients who received MR-angiography specifically (as opposed to MRI without 
angio sequences) is not stated, greatly limiting its informative value in this context. In this 
same study, DSA re-imaging of 17 NPM-SAH patients showed one dissecting supraclinoidal 
ICA aneurysm on day 10 post SAH. It is however not reported if MRA imaging was also 
performed in this patient after the aneurysm was diagnosed72.  
Fontanella et al. reported in 2011 that no vascular malformations were detected by MRA re-
imaging 21-60 days post-bleeding in 61 NPM SAH patients. These same patients had 
already received a negative repeat DSA 11-20 days after bleeding and were part of a cohort 
of 72 NPM-SAH patients. DSA re-imaging of this same cohort of 72 patients between days 
11-20 post-bleeding had revealed 9 aneurysms (12.5%)67. However, the patient data in this 
study dates from 1991-1999 and MRA specifications or the usage of 3D-reconstruction 
software are not reported.  
Andaluz et al. similarly described in 2008 no additional information gained from MRA 
performed in a series of 47 NPM SAH patients dating from 1998-2003, although the time to 
MR imaging or the imaging specifications are not reported. It is also not described if lesions 
seen in repeat DSA examinations were also visible in MRA68. DSA re-imaging – although no 
information about its timing is presented - showed relevant lesions in 10 (21.3%) of these 
same NPM-SAH patients, including 5 aneurysms. 
Maslehaty et al. reported in 2011 no diagnostic benefit of 3T TOF-MRA of the head and neck 
performed in the first 72h after SAH diagnosis in 132 NPM-SAH patients with negative initial 
DSA73. Among these same patients, 120 later underwent repeat DSA, which revealed 13 
aneurysms (10.8%). However, the time to DSA re-imaging in these patients is not reported, 
and neither if MRA was performed in these patients after the diagnosis of the aneurysm. 
Furthermore, the relatively early timing of MRA imaging after bleeding does not allow the 
generalization of the findings of this study to other time periods post-bleeding.  
There exists no prospective study comparing the diagnostic yield of DSA and MRA in the 
context of re-imaging of NPM-SAH patients, and in the absence of such higher-quality data it 
is not possible to assess the value of MRA as a noninvasive alternative to DSA with high 
certainty. The few retrospective studies which have addressed this question to date are, as 
outlined above, hardly conclusive and have for the most part insufficiently reported data. 
Therefore, although our results support the notion that MRA might be a useful alternative to 
the more invasive DSA procedure for follow-up imaging of NPM-SAH patients, more data on 




6.2.2. Timing of re-imaging 
Data regarding the exact timing of repeat imaging in NPM-SAH patients is relatively sparse, 
with many publications addressing this issue only marginally. Indeed several studies focusing 
on the re-imaging of NPM-SAH patients do not accurately, or sufficiently, report time to re-
imaging of their patients71,73–77. As such, many institutions have empirically developed their 
own re-imaging protocols for this distinct group of patients. The guidelines for the 
management of intracranial aneurysms and SAH of the European Stroke Organization, 
published in 2013, propose re-imaging 3 weeks after bleeding at the earliest, if no 
therapeutic indications exist to perform it earlier, albeit with Level of Evidence B57. 
Nonetheless, several publications within the last two decades have shown the value of re-
imaging within the first two weeks specifically, especially of DSA54,78–85. Only few recent 
studies with relatively small sample sizes do not report any findings with DSA re-imaging 
during the first two weeks48,66. In our series, in all 30 patients receiving re-imaging within the 
first 14 days after bleeding (15 receiving DSA, 24 receiving MRA, 9 receiving both), no 
bleeding source was determined. Therefore, as three true aneurysms were found during later 
re-imaging, the negative predictive value of MRA in the first two weeks was 91.3%, while that 
of DSA was 85.7%, indicating the need for further diagnostic workup beyond this acute 
phase.  
The value of medium-term imaging in the period of 2-8 weeks, on the other hand, is far less 
well examined in the literature, although some publications have reported relevant findings in 
that time period using DSA, such as Kumar et al. which found an aneurysm in 2 out of 17 
NPM-SAH patients using DSA at 6 weeks, resulting in a 11.76% yield86. These patients had 
not received an earlier repeat DSA, as re-imaging at 6 weeks post-bleeding only was 
standard practice in this study’s hospital. 
In one of the largest retrospective studies reporting time to re-imaging dating from 2013, 
Dalyai et al. described a vascular bleeding source in 7 out of 89 NPM-SAH patients (7.7%) 
receiving a third DSA examination at 6 weeks78. The bleeding sources were five aneurysms, 
one AVM and one dural arteriovenous fistula. These same patients had already undergone a 
negative re-imaging DSA examination at 1 week post-bleeding. The authors of this paper 
advocate for an extensive follow-up imaging protocol consisting of DSA both at 1 week and 6 
weeks post-bleeding. 
Delgado et al., in a retrospective analysis published in 2014 focusing on the diagnostic yield 
of repeat imaging after 14 days (median 34, range 14-69 days) after presentation in 
angiogram-negative SAH patients, found a bleeding source in 2 of 27 NPM-SAH patients 




pontine AVM seen on day 20. All patients included in this study had also received repeat 
DSA on day 7 which was deemed normal. Of note, both bleeding sources were discovered 
using CTA as a re-imaging modality, and both were retrospectively visible on the repeat DSA 
performed on day 7. The authors conclude, also in light of the results from Dalyai et al. 
described above, that re-imaging both during and after the short-term period of 2 weeks after 
bleeding is warranted in this patient group. 
Overall, the time to re-imagine remains a contentious issue66,86. The main argument for early 
re-imaging within the first 2 weeks is the prevention of re-bleeding through treatment of the 
bleeding source66,88. Indeed, the highest risk of re-bleeding is in the first few days after 
bleeding, and it carries a very poor prognosis. On the other hand, some authors cite the need 
to await the vasospasm period, the resorption of the hematoma around the aneurysm or the 
dissolution of a potential occluding thrombus inside the aneurysm as a reason to perform 
repeat neuroimaging after 4-6 weeks only72,78,89. In our series, the true aneurysms were 
discovered on days 20, 39 and 44 after SAH, and all three patients had already undergone 
multiple re-imaging examinations, with at least one of those examinations during the first 14 
days. We therefore propose, in accordance with the findings in the literature, that patients 
should receive short-term re-imaging within the first 14 days after bleeding - ideally during 
days 10-14 in order to avoid the most common period of vasospasm occurring during the 
days 7-10 after SAH. If short-term re-imaging was inconclusive, medium-term re-imaging 
near the end of this period - for example between 6-8 weeks after SAH – is indicated as well.  
Long-term follow-up of 20 patients (19 of them with MRA, one with DSA, and one patient 
receiving both imaging modalities) after 8 weeks revealed no new relevant pathologies in our 
study, and thus the negative predictive values of MRA and DSA reached 100% at 8 weeks, 
suggesting that long-term follow-up imaging is not indicated in these patients. This is in 
accordance with recent publications: although there exists only limited data on the diagnostic 
yield of neurovascular imaging later than 8 weeks after NPM-SAH, the few studies which 
have investigated this issue – in some cases performing re-imaging up to several years after 
bleeding - have all reported no relevant findings, and thus the authors unanimously 
discourage from performing it83,90–92. 
6.2.3. False-positive findings 
Our false-positive findings resulted in a positive predictive value of 75% for MRA and 50% for 
CTA at 8 weeks, whereby patients were surgically explored with no prior DSA. The 
radiological findings were small or peripheral (A1 dilation and MCA bifurcation dilation), and 
we believe a DSA examination in these patients might have prevented unnecessary surgical 




when small or peripheral, should best be corroborated on a diagnostic DSA examination 
before performing surgical exploration to avoid false-positive findings. 
6.3. Limitations of this study  
A clear limitation of this study is its retrospective character and its relatively modest number 
of patients, which limits its significance. Larger prospective trials would be helpful to 
determine the optimal time frame for re-imaging of NPM-SAH patients as well as the value of 
noninvasive neuroimaging alternatives to DSA in this setting. 
6.4. Conclusions 
1. We propose re-imaging for NPM-SAH patients not only during the first 14 days after 
bleeding (ideally 10 to 14 days), but also near the end of our medium-term imaging 
period (for example at 6-8 weeks after bleeding). In our series, all aneurysms were 
seen during the medium-term follow-up period, resulting in a negative predictive value 
MRA of 91.3% and of DSA of 85.7% during the first two weeks. This means short-
term follow-up within 14 days is not sufficient to rule out an aneurysm and medium-
term follow-up at 6-8 weeks is suggested.. 
 
2. We suggest high-quality 3 Tesla MRA imaging as a possible non-invasive alternative 
to DSA for re-imaging after NPM-SAH. In our series, all confirmed aneurysms could 
be seen in MRA. 
 
3. In re-imaging after NPM-SAH, suspect or unclear findings on CTA or MRA are best 
corroborated on a DSA examination before performing surgical exploration to avoid 
false-positive findings. This is especially true for small or peripheral findings, as they 
were in our cases.  
 
4. Long-term radiological follow-up after 8 weeks post-bleeding did not produce 
diagnostic information in our series and is unlikely to be of diagnostic benefit. The 
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MODALITY INSTANCE THE MODALITY WAS REPEATED 




DSA: #OF PATIENTS 16 2 1    
MEAN DAY POST-
ICTUS (RANGE) 
9.75 (5-15) 33.5 (23-44) 66    
TRUE-ANEURYSMS 1 2     
FALSE-POSITIVES       
CTA: #OF PATIENTS 12 7 1 1   
MEAN DAY POST-
ICTUS (RANGE) 
15.4 (1-84) 39.8 (7-140) 169 246   
TRUE-ANEURYSMS       
FALSE-POSITIVES 1      
MRA HEAD: #OF PATIENTS 27 21 8 3 3 1 
MEAN DAY POST-
ICTUS (RANGE) 










TRUE-ANEURYSMS 1 2 
 
    
FALSE-POSITIVES 1      
MRA NECK: # OF PATIENTS 3      
MEAN DAY POST-
ICTUS (RANGE) 
9.3 (6-15)      
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